(PDGF)-BB/PDGF receptor (PDGFR)-β and SDF-1α/CXCR4 axes during tumor neovascularization by increasing the recruitment of pericytes. However, the effects of interactions between these two signaling pathways in retinal microvascular pericytes remain poorly understood. Western blotting and reverse tran
DAN-NI XIANG,YI-FAN FENG,JING WANG,XI ZHANG,JING-JING SHEN,RONG ZOU,YUAN-ZHI YUAN
2019-01-01
Abstract:Stromal cell-derived growth factor (SDF)-1α acts as a ligand to C-X-C chemokine receptors 4 (CXCR4) and 7 (CXCR7), which are involved in the formation of choroidal neovascularization. Previous studies have demonstrated crosstalk between the platelet-derived growth factor (PDGF)-BB/PDGF receptor (PDGFR)-β and SDF-1α/CXCR4 axes during tumor neovascularization by increasing the recruitment of pericytes. However, the effects of interactions between these two signaling pathways in retinal microvascular pericytes remain poorly understood. Western blotting and reverse transcription-quantitative PCR were used to measure CXCR4 and CXCR7 expression in PDGF-BB-treated pericytes, whilst Cell Counting Kit-8 and Transwell migration assays were used to investigate cell viability and migration following PDGF-BB pretreatment on SDF-1α-treated pericytes. Exogenous PDGF-BB enhanced CXCR4 and CXCR7 expression through PDGFR-β in a doseand time-dependent manners. In addition, PDGF-BB increased cell viability and migration in SDF-1α-treated pericytes, which were inhibited by AMD3100 and niclosamide, inhibitors for CXCR4 and STAT3 respectively. Crosstalk between PDGF-BB/PDGFR-β and SDF-1α/CXCR4/CXCR7 were involved in the JAK2/STAT3 signaling pathway. PDGF-BB treatment enhanced CXCR4, CXCR7 and PDGFR-βexpression, which may be associated with the phosphorylation of STAT3. siRNA-PDGFR-β transfection reduced CXCR4 and CXCR7 expression in pericytes. Therefore, PDGF-BB directly targets PDGFR-β and serves an important role in regulating CXCR4 and CXCR7 expression, ultimately affecting viability and migration in SDF-1α-treated pericytes. Therefore, targeting CXCR4/CXCR7 may serve as a potential therapeutic strategy for fundus diseases. Introduction Pathological neovascularization (NV) is a common cause of blindness globally and occurs in retinal/choroidal vascular diseases, including retinopathy of prematurity (ROP), diabetic retinopathy and age-related macular degeneration. Aberrant neovascularization occurs due to the demand for oxygen and energy substrates (1). Although effective therapeutic methods for ocular NV are currently available, they are associated with certain disadvantages. For example, laser photocoagulation preserves central vision but leads to the loss of peripheral vision (2), whilst vitreous injection of anti-angiogenic agents, such as vascular endothelial growth factor (VEGF) inhibitors, have become the preferred therapy option for the inhibition of NV. However, anti‐VEGF‐treatment has little or no efficacy in certain patients because of secondary factors, including fibrosis of NV (3) and enhancement of vascular stability by pericytes (4). Therefore, efforts are being made to develop novel therapeutic strategies in addition to the classical therapies mentioned above. Platelet-derived growth factor (PDGF) is a family of chemokines and mitogens that consist of five members: PDGF-AA, PDGF-BB, PDGF-AB, PDGF-C and PDGF-D. PDGF is involved in vascular homeostasis by activating their corresponding tyrosine kinase receptors, PDGFR-α and PDGFR-β. In the eyes, PDGF participates in NV processes of the choroid, retina, and cornea by binding PDGFR, and also serves a pro-angiogenic role in a VEGF-dependent or -independent manner (5,6). The PDGF/PDGFR axis has a wide range of cellular targets and may serve a greater role compared with the VEGF/VEGFR axis. Consequently, inhibition of the PDGF/PDGFR axis may be a potential therapeutic target for diseases associated with angiogenesis. In microvessels, PDGF-BB is secreted by endothelial cells, and binds to PDGFR-β on the surfaces of pericytes. The PDGF-BB/PDGFR-β signaling pathway has essential effects on the formation and maturation of the blood-retinal barrier through the recruitment of pericytes onto new capillaries (7). Pericytes are involved in angiogenic cascades, including the formation and maturation of NV. In a laser-induced model of choroidal neovascularization (CNV), a PDGFRβ+ scaffold that limits the extent of NV formed before the formation of CNV lesions (8). PDGF inhibitor (E10030) combined with ranibizumab (an anti-VEGF agent) was demonstrated to be superior Platelet‐derived growth factor‐BB promotes proliferation and migration of retinal microvascular pericytes by up‐regulating the expression of C‐X‐C chemokine receptor types 4 DAN-NI XIANG, YI-FAN FENG, JING WANG, XI ZHANG, JING-JING SHEN, RONG ZOU and YUAN-ZHI YUAN Department of Ophthalmology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, P.R. China Received December 20, 2018; Accepted August 16, 2019 DOI: 10.3892/etm.2019.8016 Correspondence to: Dr Yuan-Zhi Yuan, Department of Ophthalmology, Zhongshan Hospital Affiliated to Fudan University, 180 Fenglin Road, Shanghai 200032, P.R. China E-mail: yuan.yuanzhi@zs-hospital.sh.cn